AAPL305.70+11.32 (+3.85%) ▲|ABBV258.05+6.99 (+2.78%) ▲|ABT94.76+2.58 (+2.80%) ▲|ACN135.97+4.84 (+3.69%) ▲|ADBE217.81+6.83 (+3.24%) ▲|AMAT602.54-48.37 (-7.43%) ▼|AMD522.02-18.86 (-3.49%) ▼|AMGN372.01+10.68 (+2.96%) ▲|AMT165.97-0.11 (-0.07%) ▼|AMZN244.89+3.19 (+1.32%) ▲|AVGO364.43-4.91 (-1.33%) ▼|AXP348.71+1.66 (+0.48%) ▲|BA224.75+6.17 (+2.82%) ▲|BAC58.56+0.20 (+0.33%) ▲|BKNG184.57+1.93 (+1.06%) ▲|BLK987.88+7.50 (+0.76%) ▲|BMY57.47+1.66 (+2.97%) ▲|BNY145.77-0.25 (-0.17%) ▼|BRK-B506.07+6.33 (+1.27%) ▲|C139.61-0.52 (-0.37%) ▼|CAT970.91-20.50 (-2.07%) ▼|CL94.61+1.85 (+1.99%) ▲|CMCSA23.18-0.56 (-2.34%) ▼|COF204.85+0.03 (+0.01%) ▲|COP103.81+0.59 (+0.57%) ▲|COST942.73+18.06 (+1.95%) ▲|CRM165.66+2.43 (+1.49%) ▲|CSCO112.46-4.55 (-3.89%) ▼|CVS104.35-0.46 (-0.44%) ▼|CVX167.96+2.27 (+1.37%) ▲|DE628.06+0.43 (+0.07%) ▲|DHR197.42+3.70 (+1.91%) ▲|DIS97.36+1.65 (+1.72%) ▲|DUK127.41+1.64 (+1.30%) ▲|EMR139.63+0.11 (+0.08%) ▲|FDX314.94+1.05 (+0.33%) ▲|GD369.46+8.19 (+2.27%) ▲|GE377.77+2.83 (+0.75%) ▲|GEV1,105.85-28.51 (-2.51%) ▼|GILD130.24+4.27 (+3.39%) ▲|GM74.95-0.57 (-0.75%) ▼|GOOG352.60-5.29 (-1.48%) ▼|GOOGL355.93-5.28 (-1.46%) ▼|GS1,020.55+0.94 (+0.09%) ▲|HD355.60+4.76 (+1.36%) ▲|HON221.84+0.09 (+0.04%) ▲|IBM286.00-0.25 (-0.09%) ▼|INTC123.42-3.60 (-2.83%) ▼|INTU272.14+5.06 (+1.89%) ▲|ISRG420.33+17.95 (+4.46%) ▲|JNJ260.40+6.42 (+2.53%) ▲|JPM333.45-0.63 (-0.19%) ▼|KO83.10+1.81 (+2.23%) ▲|LIN545.71+12.16 (+2.28%) ▲|LLY1,213.79+22.05 (+1.85%) ▲|LMT538.10+16.28 (+3.12%) ▲|LOW226.35+4.43 (+2.00%) ▲|LRCX362.86-28.41 (-7.26%) ▼|MA534.61+12.17 (+2.33%) ▲|MCD275.85+6.42 (+2.38%) ▲|MDLZ60.16+0.81 (+1.36%) ▲|MDT81.96+2.76 (+3.48%) ▲|META587.83-25.08 (-4.09%) ▼|MMM160.21+0.25 (+0.16%) ▲|MO72.42+0.88 (+1.22%) ▲|MRK128.35+2.98 (+2.38%) ▲|MS212.81+0.95 (+0.45%) ▲|MSFT388.67+4.39 (+1.14%) ▲|MU994.02-38.26 (-3.71%) ▼|NEE87.08+0.71 (+0.82%) ▲|NFLX76.92+2.73 (+3.68%) ▲|NKE44.11+1.05 (+2.44%) ▲|NOW105.02-0.79 (-0.74%) ▼|NVDA194.46-3.12 (-1.58%) ▼|ORCL140.65-1.85 (-1.30%) ▼|PEP143.17+2.01 (+1.42%) ▲|PFE24.29+0.41 (+1.70%) ▲|PG150.62+3.19 (+2.16%) ▲|PLTR129.26+3.53 (+2.80%) ▲|PM180.70+3.01 (+1.69%) ▲|QCOM175.41-6.51 (-3.58%) ▼|RTX196.78+5.00 (+2.61%) ▲|SBUX105.31+1.92 (+1.86%) ▲|SCHW96.53+0.75 (+0.78%) ▲|SO96.50+1.38 (+1.45%) ▲|SPG224.55+1.55 (+0.69%) ▲|T20.05-0.44 (-2.12%) ▼|TMO526.53+13.20 (+2.57%) ▲|TMUS173.95+0.89 (+0.51%) ▲|TSLA399.63-25.67 (-6.04%) ▼|TXN294.77-3.64 (-1.22%) ▼|UBER73.75+1.09 (+1.50%) ▲|UNH428.35+1.81 (+0.42%) ▲|UNP280.80+3.07 (+1.11%) ▲|UPS110.40+0.86 (+0.79%) ▲|USB61.55-0.41 (-0.66%) ▼|V358.60+7.52 (+2.14%) ▲|VZ41.09-0.91 (-2.16%) ▼|WFC85.50-0.44 (-0.51%) ▼|WMT111.52+2.70 (+2.48%) ▲|XOM136.84+0.56 (+0.41%) ▲|AAPL305.70+11.32 (+3.85%) ▲|ABBV258.05+6.99 (+2.78%) ▲|ABT94.76+2.58 (+2.80%) ▲|ACN135.97+4.84 (+3.69%) ▲|ADBE217.81+6.83 (+3.24%) ▲|AMAT602.54-48.37 (-7.43%) ▼|AMD522.02-18.86 (-3.49%) ▼|AMGN372.01+10.68 (+2.96%) ▲|AMT165.97-0.11 (-0.07%) ▼|AMZN244.89+3.19 (+1.32%) ▲|AVGO364.43-4.91 (-1.33%) ▼|AXP348.71+1.66 (+0.48%) ▲|BA224.75+6.17 (+2.82%) ▲|BAC58.56+0.20 (+0.33%) ▲|BKNG184.57+1.93 (+1.06%) ▲|BLK987.88+7.50 (+0.76%) ▲|BMY57.47+1.66 (+2.97%) ▲|BNY145.77-0.25 (-0.17%) ▼|BRK-B506.07+6.33 (+1.27%) ▲|C139.61-0.52 (-0.37%) ▼|CAT970.91-20.50 (-2.07%) ▼|CL94.61+1.85 (+1.99%) ▲|CMCSA23.18-0.56 (-2.34%) ▼|COF204.85+0.03 (+0.01%) ▲|COP103.81+0.59 (+0.57%) ▲|COST942.73+18.06 (+1.95%) ▲|CRM165.66+2.43 (+1.49%) ▲|CSCO112.46-4.55 (-3.89%) ▼|CVS104.35-0.46 (-0.44%) ▼|CVX167.96+2.27 (+1.37%) ▲|DE628.06+0.43 (+0.07%) ▲|DHR197.42+3.70 (+1.91%) ▲|DIS97.36+1.65 (+1.72%) ▲|DUK127.41+1.64 (+1.30%) ▲|EMR139.63+0.11 (+0.08%) ▲|FDX314.94+1.05 (+0.33%) ▲|GD369.46+8.19 (+2.27%) ▲|GE377.77+2.83 (+0.75%) ▲|GEV1,105.85-28.51 (-2.51%) ▼|GILD130.24+4.27 (+3.39%) ▲|GM74.95-0.57 (-0.75%) ▼|GOOG352.60-5.29 (-1.48%) ▼|GOOGL355.93-5.28 (-1.46%) ▼|GS1,020.55+0.94 (+0.09%) ▲|HD355.60+4.76 (+1.36%) ▲|HON221.84+0.09 (+0.04%) ▲|IBM286.00-0.25 (-0.09%) ▼|INTC123.42-3.60 (-2.83%) ▼|INTU272.14+5.06 (+1.89%) ▲|ISRG420.33+17.95 (+4.46%) ▲|JNJ260.40+6.42 (+2.53%) ▲|JPM333.45-0.63 (-0.19%) ▼|KO83.10+1.81 (+2.23%) ▲|LIN545.71+12.16 (+2.28%) ▲|LLY1,213.79+22.05 (+1.85%) ▲|LMT538.10+16.28 (+3.12%) ▲|LOW226.35+4.43 (+2.00%) ▲|LRCX362.86-28.41 (-7.26%) ▼|MA534.61+12.17 (+2.33%) ▲|MCD275.85+6.42 (+2.38%) ▲|MDLZ60.16+0.81 (+1.36%) ▲|MDT81.96+2.76 (+3.48%) ▲|META587.83-25.08 (-4.09%) ▼|MMM160.21+0.25 (+0.16%) ▲|MO72.42+0.88 (+1.22%) ▲|MRK128.35+2.98 (+2.38%) ▲|MS212.81+0.95 (+0.45%) ▲|MSFT388.67+4.39 (+1.14%) ▲|MU994.02-38.26 (-3.71%) ▼|NEE87.08+0.71 (+0.82%) ▲|NFLX76.92+2.73 (+3.68%) ▲|NKE44.11+1.05 (+2.44%) ▲|NOW105.02-0.79 (-0.74%) ▼|NVDA194.46-3.12 (-1.58%) ▼|ORCL140.65-1.85 (-1.30%) ▼|PEP143.17+2.01 (+1.42%) ▲|PFE24.29+0.41 (+1.70%) ▲|PG150.62+3.19 (+2.16%) ▲|PLTR129.26+3.53 (+2.80%) ▲|PM180.70+3.01 (+1.69%) ▲|QCOM175.41-6.51 (-3.58%) ▼|RTX196.78+5.00 (+2.61%) ▲|SBUX105.31+1.92 (+1.86%) ▲|SCHW96.53+0.75 (+0.78%) ▲|SO96.50+1.38 (+1.45%) ▲|SPG224.55+1.55 (+0.69%) ▲|T20.05-0.44 (-2.12%) ▼|TMO526.53+13.20 (+2.57%) ▲|TMUS173.95+0.89 (+0.51%) ▲|TSLA399.63-25.67 (-6.04%) ▼|TXN294.77-3.64 (-1.22%) ▼|UBER73.75+1.09 (+1.50%) ▲|UNH428.35+1.81 (+0.42%) ▲|UNP280.80+3.07 (+1.11%) ▲|UPS110.40+0.86 (+0.79%) ▲|USB61.55-0.41 (-0.66%) ▼|V358.60+7.52 (+2.14%) ▲|VZ41.09-0.91 (-2.16%) ▼|WFC85.50-0.44 (-0.51%) ▼|WMT111.52+2.70 (+2.48%) ▲|XOM136.84+0.56 (+0.41%) ▲|
34.6 C
New York
Thursday, July 2, 2026

Tag: progress

newssourceFORcompanyinformationcontent1releasesmarket

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

APP Group Strengthens Japan-Indonesia Economic Ties Through Sustainable Development

JAKARTA, Indonesia, June 12, 2025 /PRNewswire/ -- As Japan accelerates its Green Growth Strategy to achieve carbon neutrality and economic sustainability, APP Group is...

Community Healthcare Trust Releases 2024 Corporate Sustainability Report

FRANKLIN, Tenn., June 11, 2025 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) (the "Company") today announced the release of its second Corporate Sustainability...

National Corporate Housing Releases Annual Corporate Social Responsibility Report Celebrating 25 Years Of Positive Impact

GREENWOOD VILLAGE, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- National Corporate Housing has released its annual Corporate Social Responsibility Report that showcases the company’s commitment to focusing on people, operating sustainably, and enriching community.

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board of Directors

Noted pharmaceutical industry executive Frederick Beddingfield, MD, PhD, has joined the Neurodon Board of Directors, bringing years of industry leadership.

Renée James will join Portland General Electric board of directors, effective June 11, 2025

PORTLAND, Ore., June 11, 2025 /PRNewswire/ -- Renée James has been appointed to the Portland General Electric (NYSE:POR) ("PGE" or the "Company") board of...

Maple Leaf Foods Inc. shareholders approve spin-off of Canada Packers and elect Board of Directors at the 2025 Annual and Special Meeting

TSX: MFIwww.mapleleaffoods.com MISSISSAUGA, ON, June 11, 2025 /CNW/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or the "Company") (TSX: MFI) announced today that its...

Sempra Infrastructure and JERA Sign Heads of Agreement for U.S. LNG Supply

HOUSTON, June 11, 2025 /PRNewswire/ -- Sempra Infrastructure, a subsidiary of Sempra (NYSE: SRE), today announced it has executed a non-binding heads of agreement (HOA)...

Dana Incorporated Announces Agreement to Sell Off-Highway Business for $2.7 Billion; $1 Billion Capital Return Authorization

Price represents 7x the expected 2025 adjusted EBITDA of the Off-Highway business Strengthens balance sheet through substantial debt reductionPositions Dana with a streamlined go-to-market approach...

Equifax Introduces Optimal Path™ Interactive Score Planner

Powered by the Equifax Cloud™ and Patented EFX.AI Capabilities, Optimal Path Gives Organizations a Powerful Tool to Help U.S. Consumers Advance Financial Health and...

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers